February 21, 2017

The Scripps Research Institute Announces New Board Members and Chairman of the Board The Scripps Research Institute (TSRI), one of the worlds largest, private, non-profit research organizations, today announced the appointment of nine new members to its Board of Directors, including John D. Diekman, who will serve as chairman of the board.

February 21, 2017

LA JOLLA, CA & JUPITER, FL February 21, 2017 The Scripps Research Institute (TSRI), one of the worlds largest, private, non-profit research organizations, today announced the appointment of nine new members to its Board of Directors, including John D. Diekman, who will serve as chairman of the board. Diekman replaces Richard A. Gephardt, who is retiring from the board after seven years of service.

I am pleased to welcome such an esteemed, world-renowned group of education, business and scientific leaders to TSRIs Board of Directors, said Peter G. Schultz, Ph.D., President of TSRI and the California Institute for Biomedical Research (Calibr). The unique and extensive expertise of our existing and newly appointed board members will be critical to the advancement of our vision of a self-sustaining, bench-to-bedside, non-profit model that not only advances science through basic research but also rapidly translates new discoveries into life-saving medicines for the public benefit.

On behalf of the entire Institute, I would also like to thank Richard Gephardt for his insightful leadership and steadfast support over the past seven years. His wide-ranging experience and commitment to advancing our mission is greatly appreciated, and we wish Richard all the best.

TSRI Board of Director Appointees

Chairman John D. Diekman, Ph.D.

Diekman is a Founding Partner of 5AM Ventures, a life science venture capital firm in San Francisco. Prior to founding 5AM in 2002, Diekman was a Founder and Managing Director of Bay City Capital. Previously, he was Chairman and Chief Executive Officer of Affymetrix, and Chairman and Managing Director of Affymax.

Diekman currently serves as chairman of the board of IDEAYA Biosciences and as a board member of Wildcat Discovery Technologies. He is a Charter Trustee of Princeton University and a former Trustee of The California Institute of Technology and of The Scripps Research Institute. Diekman serves on the Schaeffer Center for Health Policy and Economics Advisory Board at the University of Southern California and is an Honorary Officer of the Order of Australia.

He received his doctoral degree from Stanford University and holds an honorary doctoral degree from Australia's Monash University.

Herb Boyer, Ph.D.

Boyer is internationally recognized for his pioneering discovery of recombinant DNA, which has led to numerous life-saving medicines. He co-founded Genentech in 1976 with the late venture capitalist Robert Swanson, breaking new ground for both life science technology and new business models. He is now retired and is Professor Emeritus of Biochemistry and Biophysics at the University of California, San Francisco.

In 2004, Business Week magazine named Boyer one of the Greatest Innovators of the Past 75 Years, and he was featured on the cover of TIME magazine in 1981 with a story titled, Shaping Life in the Lab: The Boom in Genetic Engineering, Genentechs Herb Boyer.

Boyer has received numerous prestigious awards for his work including the National Medal of Technology and Innovation, the National Medal of Science, the Lemelson-MIT Prize and the Albany Medical Prize. He is an elected member of the National Academy of Sciences, the American Academy of Arts and Sciences and the National Inventors Hall of Fame. He earned his doctoral degree from the University of Pittsburgh.

Gerald Chan, Ph.D.

Chan co-founded Morningside, a private equity and venture capital firm, in 1986.

In life science, Morningside has been the founding or major investor in many biotechnology companies. In oncology, the investments include oncolytic viruses (Biovex, DNATrix), immuno-oncology (Aduro), modified cytotoxic agents (Nucana) and novel therapeutic targets (CellCentric, K-Gen, Vigeo). Investments in infectious diseases include antibiotics (MicuRx, Artugen), prophylactic vaccines (Matrivax) and antivirals (Atea). Investments in other therapeutic areas include metabolic diseases (CVI), autoimmune diseases (Kezar), CNS disorders (Orthogonal, Pinteon, Cognoa, Cognito) and rare orphan diseases (Stealth, Apellis).

Chan received his doctoral degree from Harvard University and conducted his post-doctoral fellowship at Dana-Farber Cancer Institute.

Mark Edwards

As Founder and Managing Director of Recombinant Capital (Recap) from 1988 until its sale to Deloitte in 2008, Edwards supervised the creation and maintenance of several databases relating to the development and commercialization of pharmaceutical products, including the Recap Corporate Alliances Database. Over this period, Edwards and Recap were retained by more than 50 companies to assist in the negotiation of biopharma alliances. In 2011, Edwards founded Bioscience Advisors, Inc. (Biosci), a consulting and database firm focused on biopharma alliances.

Edwards serves on the boards of directors of AcelRx and Calibr. In 2008, Edwards was awarded a Lifetime Achievement Award by the American Liver Foundation for two decades of leadership, thoughtful insights and detailed analysis of the biotechnology industry. He holds a Master of Business Administration from Stanford University.

Isy Goldwasser

Goldwasser is Co-Founder and Chief Executive Officer of Thync, Inc. Prior to founding Thync, Goldwasser was Chief Executive Officer of Symyx Technologies, where he was the companys first employee. In addition to his 16 years at Symyx, Goldwasser was Khosla Ventures Entrepreneur-in-Residence in 2010. He is a named inventor on more than 30 U.S., European and Canadian patents

LINK:	https://www.scripps.edu/news-and-events/press-room/2017/20170220board....
	See more stories from scripps

Most recent headlines